MGX (Metagenomi Therapeutics) Scaled Net Operating Assets: 0.17 (As of Mar. 2026)


MGX Metagenomi Therapeutics Inc MGX
10 GF Score
Price $1.20
! 4 Warning Signs
View Full Analysis

What is Metagenomi Therapeutics Scaled Net Operating Assets?

Metagenomi Therapeutics MGX 10 Scaled Net Operating Assets is 0.17 as of Mar. 2026. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Metagenomi Therapeutics's operating assets for the quarter that ended in Mar. 2026 was $56.79 Mil. Metagenomi Therapeutics's operating liabilities for the quarter that ended in Mar. 2026 was $19.98 Mil. Metagenomi Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was $221.10 Mil. Therefore, Metagenomi Therapeutics's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was 0.17.

Metagenomi Therapeutics Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Metagenomi Therapeutics's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Metagenomi Therapeutics Scaled Net Operating Assets Chart

Metagenomi Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Scaled Net Operating Assets
-0.65 -2.94 -0.87 0.09 0.12

Metagenomi Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.11 0.13 0.16 0.17

MGX vs KALA, HYPD, APLM: Scaled Net Operating Assets Comparison

For the Biotechnology subindustry, Metagenomi Therapeutics's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Metagenomi Therapeutics Scaled Net Operating Assets vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Metagenomi Therapeutics's Scaled Net Operating Assets falls into.


MGX
10GF Score
Metagenomi Therapeutics Inc MGX
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Metagenomi Therapeutics Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Metagenomi Therapeutics's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2025 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2025 )
=(Operating Assets (A: Dec. 2025 )-Operating Liabilities (A: Dec. 2025 ))/Total Assets (A: Dec. 2024 )
=(60.304-21.85)/324.599
=0.12

where

Operating Assets(A: Dec. 2025 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=221.103 - 160.799
=60.304

Operating Liabilities(A: Dec. 2025 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=62.507 - 34.632 - 6.025
=21.85

Metagenomi Therapeutics's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(56.791-19.982)/221.103
=0.17

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=196.953 - 140.162
=56.791

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=59.168 - 33.081 - 6.105
=19.982

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Scaled Net Operating Assets of 0.17 mean?
Metagenomi Therapeutics (MGX) has a Scaled Net Operating Assets of 0.17 as of Mar. 2026. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Metagenomi Therapeutics and its competitors.
Is Metagenomi Therapeutics' Scaled Net Operating Assets too high?
Metagenomi Therapeutics' current Scaled Net Operating Assets is 0.17. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' Scaled Net Operating Assets compare to KALA and HYPD?
Metagenomi Therapeutics' Scaled Net Operating Assets of 0.17 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Scaled Net Operating Assets for a Biotechnology company?
A good Scaled Net Operating Assets depends on the Biotechnology industry context. However, Scaled Net Operating Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Scaled Net Operating Assets mean?
A high Scaled Net Operating Assets can signal that a stock is expensive relative to its fundamentals. Scaled net operating assets equals current-period operating assets less operating liabilities less prior-period total assets. View historical data on Metagenomi Therapeutics and its competitors. Metagenomi Therapeutics's current Scaled Net Operating Assets is 0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current Scaled Net Operating Assets of 0.17. The current Scaled Net Operating Assets is 0.17. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Scaled Net Operating Assets calculated?
Scaled Net Operating Assets is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current Scaled Net Operating Assets is 0.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Metagenomi Therapeutics Business Description

Address 5959 Horton Street, 7th Floor, Emeryville, CA, USA, 94608
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score

Get the complete analysis for MGX

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.20
Price